Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354378 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL30338216 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29908078 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL12254866 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL29400089 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14997839 | 1.00 | KMT2A (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL12658035 | 0.95 | PTPN1 (0.58) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL14719947 | 0.93 | KMT2A (0.57) | KMT2AMDM4TP53TLR2CASP3 | |
| SCHEMBL22712859 | 0.93 | TLR2 (0.54) | KMT2AMDM4TP53TLR2CASP3 | |
| D-Glutamate SCHEMBL28574794 | 0.93 | MDM4 (0.52) | KMT2AMDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005719-A | SIRP alpha blocker polypeptide, construction method and application thereof | 华东理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-115340472-B | Glutamic acid derivative and synthesis method and application thereof | 合肥工业大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117800876-A | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| CN-117800876-B | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2025-11-14 | — | — | CN | disclosed |
| CN-120118195-A | Phage lyase analogues and uses thereof | 上海多米瑞生物技术有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250041443-A1 | COMPOSITIONS FOR INTRODUCING RNA INTO CELLS | ETHRIS GMBH (DE) | 2025-02-06 | — | — | US | disclosed |
| EP-4469468-A1 | PROCESS FOR THE PREPARATION OF LINACLOTIDE | Fresenius Kabi iPSUM S.r.l. (IT) | 2024-12-04 | — | — | EP | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0963999-A1 | E2F ACTIVITY INHIBITORY COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0865283-A1 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPACIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Scriptgen Pharmaceuticals Inc. (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5756825-A | A CHELATING COMPOUND COMPRISES PROTEIN CONJUGATION FUNCTION AND A CHELATE FUNCTION; THE CHELATING COMPOUND IS 3-CARBOXYPROPYL N-(TRIS(2-((N-(BENZYLOXY)AMINO)CARBONYL)ETHYL )-METHYL)SUCCINAMATE | UAB RESEARCH FOUNDATION | 1998-05-26 | — | — | US | disclosed |
| WO-1997009053-A1 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPATIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1994005627-A1 | HYDROXAMIC ACID-BASED BIFUNCTIONAL CHELATING COMPOUNDS | UAB RESEARCH FOUNDATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | KMT2A 2126/4885MDM4 3299/4885TP53 2320/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | KMT2A 2327/4885MDM4 3919/4885TP53 1509/4885 |
| US-20250041443-A1 | COMPOSITIONS FOR INTRODUCING RNA INTO CELLS | NSUN3, ABCB4, RNMT | KMT2A 1671/4885MDM4 1021/4885TP53 948/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | KMT2A 2985/4885MDM4 3016/4885TP53 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.